Santarus seeks US FDA nod to begin phase III trial of rifamycin SV MMX in travellers' diarrhoea
Monday, January 04, 2010 10:00 IST San Diego
Santarus, Inc, a specialty biopharmaceutical company, has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) requesting
